Market revenue in 2023 | USD 10.6 million |
Market revenue in 2030 | USD 30.1 million |
Growth rate | 16.2% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Service |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Service |
Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crispr and cas genes market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 78.3% in 2023. Horizon Databook has segmented the Mexico crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
In Mexico, human genome editing and human genetic engineering fields are not explicitly regulated. The birth of the first three-parent baby, in September 2016, by using maternal spindle transfer for mitochondrial-replacement therapy raised several ethical concerns in this region.
Therefore, in Mexico, the clinical application of CRISPR genome editing technology is highly regulated and supervised. Moreover, penalties are imposed for use of procedures that have not been safety-tested in humans. In addition, there is no determined regulatory status of gene editing in plant products or plants in Mexico.
Gene-edited products are regulated under restrictive laws developed for transgenic GMOs. These factors limit the use of CRISPR in Mexico to some extent. However, several research laboratories have established a set of guidelines based on the international regulatory framework of CRISPR applications in clinical research studies, which is expected to positively influence ongoing research studies in Mexico.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico crispr and cas genes market , including forecasts for subscribers. This country databook contains high-level insights into Mexico crispr and cas genes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account